EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma

Takuya Tsujino iD, Keita Tamura iD, Rikiya Taoka iD, Makito Miyake iD, Keita Kobayashi iD, Yutaro Sasaki iD, Kohei Ogawa iD, Shuichi Tatarano iD, Satoshi Katayama iD, Minoru Kato, Yohei Abe iD, Yuki Oda iD und 9 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70682 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Takuya Tsujino und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enfortumab vedotin (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma. Further characterization of clinical heterogeneity and toxicity may complement existing Japanese real‐world data.

Methods

We conducted a multicenter prospective study across 11 Japanese institutions. Consecutive patients who initiated EVP for unresectable locally advanced or metastatic urothelial carcinoma between October 2024 and December 2025 were included. Patient characteristics, treatment exposure, response, adverse events, and short‐term survival outcomes were descriptively analyzed.

Results

A total of 172 patients were included. Median age was 75 years, 73.8% had creatinine clearance < 60 mL/min, and 76.7% were classified as cisplatin‐unfit using modified Galsky criteria. Upper tract urothelial carcinoma accounted for 35.5% of cases. Median follow‐up was 7.1 months. Early EV dose reduction was recorded in 44.8% of patients, and discontinuation of at least one agent occurred in 61.0%. Among 158 response‐evaluable patients, the best overall objective response rate was 62.7% and the disease control rate was 82.3%; corresponding all‐treated estimates were 57.6% and 75.6%, respectively. Skin reaction was the most common adverse event, while pneumonitis was a major cause of treatment discontinuation.

Conclusions

In Japanese real‐world practice, EVP was frequently used in older, renally impaired, cisplatin‐unfit patients. Response was clinically meaningful among evaluable patients, but interpretation requires caution because of short follow‐up and denominator‐dependent response estimates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellUrologic NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntibodies, MonoclonalJapanProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

cisplatin ineligibilityenfortumab vedotinpembrolizumabreal‐world evidencetreatment‐related adverse eventsurothelial carcinoma

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalenfortumab vedotinpembrolizumab

Autor:innen und Institutionen

  • Department of Urology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Department of Urology, Nara Medical University, Kashihara, Japan.
  • Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
  • Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.

ORCID-Profile: Takuya Tsujino, Keita Tamura, Rikiya Taoka, Makito Miyake, Keita Kobayashi, Yutaro Sasaki, Kohei Ogawa, Shuichi Tatarano, Satoshi Katayama, Yohei Abe, Yuki Oda, Koichiro Wada, Junya Furukawa, Motoo Araki, Koji Shiraishi, Teruo Inamoto, Haruhito Azuma

Zitieren

APA

Tsujino, T., Tamura, K., Taoka, R., Miyake, M., Kobayashi, K., Sasaki, Y., Ogawa, K., Tatarano, S., Katayama, S., Kato, M., Abe, Y., Oda, Y., Wada, K., Furukawa, J., Araki, M., Enokida, H., Shiraishi, K., Inoue, K., Inamoto, T., …, & West Japan Uro‐oncology Collaboration Group (2026). Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma. International Journal of Urology. https://doi.org/10.1111/iju.70682

Vancouver

Tsujino T, Tamura K, Taoka R, Miyake M, Kobayashi K, Sasaki Y, et al. Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma. International Journal of Urology. 2026. doi:10.1111/iju.70682

BibTeX
@article{Tsujino2026,
  author = {Tsujino, Takuya and Tamura, Keita and Taoka, Rikiya and Miyake, Makito and Kobayashi, Keita and Sasaki, Yutaro and Ogawa, Kohei and Tatarano, Shuichi and Katayama, Satoshi and Kato, Minoru and Abe, Yohei and Oda, Yuki and Wada, Koichiro and Furukawa, Junya and Araki, Motoo and Enokida, Hideki and Shiraishi, Koji and Inoue, Keiji and Inamoto, Teruo and Azuma, Haruhito and West Japan Uro‐oncology Collaboration Group, West Japan Uro‐oncology Collaboration Group},
  title = {Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70682}
}
Kostenlos starten →